FDA-filed SPL labeling · retrieved through openFDA

Lisdexamfetamine

Lisdexamfetamine is a prescription CNS stimulant used to treat ADHD in adults and children age 6 and older, and moderate to severe binge eating disorder in adults.

Brand names VyvanseAryntaLisdexamfetamine Dimesylate
Drug class ⓘ Central Nervous System Stimulant
Rx Schedule CII Forms 3 Route Oral
Dr. Brian Staiger, PharmD, BCPS
Reviewed by Last reviewed Jul 10, 2026
🧬 Where this information comes from Click to expand

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 32 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →

At a glance
Linked label effectiveMay 22, 2026
Clinical labels in scope ⓘ32
AvailabilityRx
Earliest approval/marketing year ⓘ2007
FDA-listed product records ⓘ376
Boxed warningYes
How we combine label and product data →
⭐ Lisdexamfetamine at a glance The quick version — the full detail is in the Patient Information Guide below.
💊
HelloPharmacist Editorial Team Bottom Line
Lisdexamfetamine is a controlled CNS stimulant used to treat ADHD in people age 6 and older and moderate to severe binge eating disorder in adults. It carries a real risk of misuse and addiction, so it should be taken exactly as prescribed — no more, no less. Regular check-ins with your prescriber for heart health, mood, and growth (in children) are an important part of safe use.
How we write & review this content — our editorial policy →
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾

Lisdexamfetamine has a high risk of misuse, abuse, and addiction. It is a controlled substance. Misusing it — especially at higher doses or by snorting or injecting it — can lead to overdose and death. Before prescribing, your doctor should assess your risk of abuse. Keep this medication stored safely (preferably locked) and never share it with others. Your doctor will regularly check for signs of misuse throughout treatment.

Read the full warning on DailyMed →

📖 Lisdexamfetamine: Patient Information Guide

A plain-language walkthrough of Lisdexamfetamine — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.

🎯What it's used for▾

Lisdexamfetamine is a CNS stimulant approved to treat the following conditions across its available products:

  • ADHD (Attention Deficit Hyperactivity Disorder) in adults and children age 6 and older — supported by Lisdexamfetamine Dimesylate capsules, Lisdexamfetamine Dimesylate chewable tablets, Vyvanse capsules and chewable tablets, and Arynta oral solution
  • Moderate to severe binge eating disorder (BED) in adults — supported by Lisdexamfetamine Dimesylate capsules, Lisdexamfetamine Dimesylate chewable tablets, Vyvanse capsules and chewable tablets, and Arynta oral solution
  • Not approved or recommended for weight loss or treatment of obesity in any form or brand
  • Not recommended in children under age 6 — younger children experience higher drug exposure and more side effects at the same doses
  • BED approval applies to adults only; safety and effectiveness for BED have not been established in patients under 18
⚙️How it works▾

Lisdexamfetamine is a prodrug — it is inactive when you swallow it and gets converted by your body into its active form, dextroamphetamine. Dextroamphetamine blocks the reabsorption (reuptake) of two brain chemicals — dopamine and norepinephrine — and triggers their increased release. This raises the activity of these chemical messengers in the brain. The exact way this improves ADHD symptoms or reduces binge eating episodes is not fully known.

💊How it's taken▾

All forms of lisdexamfetamine are taken once daily by mouth in the morning, with or without food. Taking it in the afternoon should be avoided because it can interfere with sleep. Your prescriber will start you on a lower dose and adjust it gradually based on how you respond.

  • Capsules (Lisdexamfetamine Dimesylate, Vyvanse): can be swallowed whole or opened and mixed into water, yogurt, or orange juice — drink the entire mixture immediately
  • Chewable tablets (Lisdexamfetamine Dimesylate, Vyvanse): must be chewed thoroughly before swallowing; do not split the dose
  • Oral solution (Arynta): use the dosing syringe and bottle adapter provided; discard unused solution 30 days after first opening

Always follow your prescriber's instructions and your prescription label exactly. People with severe kidney disease may require lower maximum doses.

🤒Side effects — in detail▾

The most commonly reported side effects include:

  • Decreased appetite or loss of appetite
  • Trouble sleeping (insomnia)
  • Dry mouth
  • Nausea, vomiting, or diarrhea
  • Weight loss
  • Feeling jittery or anxious
  • Increased heart rate
  • Dizziness or upper abdominal pain

Serious reactions that need immediate medical attention include: signs of serotonin syndrome (agitation, high fever, muscle twitching, rapid heartbeat), new or worsening psychiatric symptoms (hallucinations, mania), poor circulation in the fingers or toes, and significant changes in blood pressure or heart rate. In children, slow growth or inadequate weight gain should be reported to the prescriber.

⚠️Warnings & precautions▾
  • Abuse and addiction risk: Lisdexamfetamine is a Schedule II controlled substance with a high potential for misuse. Misuse — especially snorting or injecting — can cause overdose and death. Store it safely and never share it.
  • Heart risks: Can raise blood pressure and heart rate. Sudden death has occurred in patients with serious heart conditions taking CNS stimulants. Not for use in people with structural heart disease, cardiomyopathy, serious arrhythmias, or coronary artery disease.
  • Psychiatric effects: Can trigger psychosis, mania, or mood changes, even in people with no prior mental health history. May worsen existing psychiatric conditions.
  • Growth in children: Long-term use can slow height and weight gain in children. Regular monitoring is required; treatment may need to be paused.
  • Serotonin syndrome: A potentially life-threatening reaction can occur when combined with serotonergic drugs. Symptoms include agitation, fever, rapid heart rate, and muscle stiffness.
  • Peripheral vasculopathy (Raynaud's phenomenon): Reduced blood flow to fingers and toes has been reported. Report numbness, color changes, or sores on the fingers or toes to your doctor.
  • Tics and Tourette's syndrome: Can trigger or worsen motor and verbal tics. Screen for tics before starting treatment.
🔀What it interacts with▾

Lisdexamfetamine can interact with several types of medications — tell your prescriber and pharmacist about everything you take:

  • MAO inhibitors (MAOIs): Strictly contraindicated — combining can cause a dangerous hypertensive crisis (sudden, severe high blood pressure) and potentially fatal neurological effects. Wait at least 14 days after stopping an MAOI before starting lisdexamfetamine.
  • Serotonergic drugs (SSRIs, SNRIs, triptans, tricyclic antidepressants, tramadol, fentanyl, lithium, buspirone, St. John's Wort): Raise the risk of serotonin syndrome — a potentially life-threatening reaction.
  • CYP2D6 inhibitors: Can increase blood levels of dextroamphetamine, raising side effects and serotonin syndrome risk.
  • Urinary alkalinizing agents (e.g., certain antacids, sodium bicarbonate): Raise amphetamine blood levels — avoid combining.
  • Urinary acidifying agents: Lower amphetamine blood levels, which may reduce the medication's effectiveness.
  • Tricyclic antidepressants: Can dramatically increase amphetamine's effects on the brain and heart — requires careful monitoring.

This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.

📋Before taking it▾
  • Tell your doctor if you have any heart condition — including structural heart defects, cardiomyopathy, arrhythmia, or coronary artery disease
  • Tell your doctor about any personal or family history of bipolar disorder, depression, psychosis, suicide, or mania
  • Tell your doctor if you or a family member have tics or Tourette's syndrome
  • Pregnancy: May cause premature delivery, low birth weight, or withdrawal symptoms in newborns; discuss risks with your doctor
  • Breastfeeding is not recommended — the drug passes into breast milk and may affect the infant's heart, blood pressure, and growth
  • Children under 6: Not recommended — higher drug exposure and more frequent adverse reactions have been observed in this age group
  • Severe kidney disease or end-stage kidney disease: Requires a lower maximum dose; lisdexamfetamine cannot be removed by dialysis
  • Older adults: Start at the lower end of the dose range; more likely to have kidney, liver, or heart issues that affect how the drug behaves
  • Tell your prescriber about all medications, supplements, and herbal products you take, particularly antidepressants or anything that affects serotonin
  • People with aspirin sensitivity should note that the 20 mg and 40 mg capsule strengths of lisdexamfetamine dimesylate contain tartrazine (FD&C yellow No. 5), which can cause allergic reactions in susceptible individuals
🚑If you take too much▾

Taking too much lisdexamfetamine can cause serious and life-threatening effects, including dangerously fast or irregular heartbeat, very high or very low blood pressure, seizures, hallucinations, extreme agitation, high fever, and loss of consciousness. In severe cases, overdose can lead to heart attack, stroke, or death.

If you think you or someone else has taken too much, call the Poison Help line at 1-800-222-1222 or seek emergency medical care immediately. Note that lisdexamfetamine cannot be removed from the body by dialysis.

📡Pharmacodynamics — effects in the body▾

Dextroamphetamine — the active form lisdexamfetamine is converted into — works by blocking the reuptake of norepinephrine and dopamine back into nerve cells, and by triggering the increased release of these brain chemicals. This raises their levels in the spaces between nerve cells. On average, the medication causes modest increases in blood pressure (about 2–4 mm Hg) and heart rate (about 3–6 beats per minute), though some individuals experience larger changes. These cardiovascular effects are why blood pressure and pulse are monitored during treatment.

🔬Pharmacokinetics — how your body processes it▾

After you take lisdexamfetamine by mouth, it is absorbed and then converted in the body into its active form, dextroamphetamine. Studies have confirmed this conversion process is predictable and consistent across a range of doses in both adults and children ages 6 and older. The capsule and chewable tablet forms have been studied in adults; the capsule form has also been studied in children ages 6 to 12. Because lisdexamfetamine must be converted to work, it is designed to have a lower abuse potential compared with direct-acting amphetamines — it does not directly bind to the sites responsible for dopamine and norepinephrine reuptake in its original form.

📦How to store it▾

Dispense in a tight, light-resistant container as defined in the USP. Store at room temperature 20ºC to 25ºC (68ºF to 77ºF); excursions permitted between 15ºC to 30ºC (59ºF to 86ºF) .

📄 Written from Lisdexamfetamine’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →

126

Supplements & herbs that interact with Lisdexamfetamine

126 supplements and herbal products have documented interactions with Lisdexamfetamine in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.

Severity mix
  • Major · 6
  • Moderate · 98
  • Minor · 22
ACTIVATED CHARCOAL Major EPHEDRA Major LITHIUM Major PEYOTE Major RAUVOLFIA VOMITORIA Major SIDA CORDIFOLIA Major 1,3-DMAA Moderate 1,3-DMBA Moderate +118 more
Every supplement checked against Lisdexamfetamine — ranked by severity The full interaction hub: 6 major · 98 moderate · 22 minor · every one linked to its full report. Check Lisdexamfetamine against your exact supplements

Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

🩺 Pharmacist Counseling Corner

Quick, plain-English answers to the questions patients ask most about Lisdexamfetamine — the kind of thing our pharmacy team would talk through with you at the counter.

What exactly is lisdexamfetamine used for? ▾
Lisdexamfetamine is used to treat two conditions: ADHD in adults and kids age 6 and older, and moderate to severe binge eating disorder in adults. It's not approved for weight loss — even though appetite changes are a known side effect. If you're taking it for BED, that's a legitimate FDA-approved use, not an off-label one.
What are the most common side effects I should expect? ▾
The most common ones are decreased appetite, trouble sleeping, dry mouth, nausea, and weight loss. Some people also feel jittery or anxious, especially early on. Most of these tend to be most noticeable when you first start or when your dose goes up. Taking it in the morning (not afternoon) helps with the sleep issue.
Is this medication addictive? Should I be worried? ▾
Lisdexamfetamine is a controlled substance with a real potential for misuse and addiction — that's something your doctor weighs carefully before prescribing it. When taken exactly as prescribed, the risk is much lower. The key things: take only your prescribed dose, never share it, and store it safely — ideally in a locked place. Never crush, snort, or inject it; that dramatically increases the risk of overdose.
Are there any medications I absolutely can't take with this? ▾
Yes — MAO inhibitors (MAOIs, a type of antidepressant) are a hard no. Combining them can cause a dangerous spike in blood pressure and serious neurological effects. You need to wait at least 14 days after stopping an MAOI before starting lisdexamfetamine. You should also be careful with other antidepressants, migraine medications called triptans, and herbal supplements like St. John's Wort, because they can increase the risk of a serious reaction called serotonin syndrome. Always tell every prescriber and pharmacist what you're taking.
My child is taking this — should I be watching for anything specific? ▾
Yes, a few things. Watch their appetite and weight — decreased appetite and weight loss are common, and long-term use can slow height and weight gain in children. Their doctor should check height and weight regularly. Also watch for any changes in mood, unusual behaviors, or new tics (repetitive movements or sounds). If you notice any of those, or if your child seems to have heart-related symptoms like chest pain or shortness of breath, contact the doctor right away.
Can I take lisdexamfetamine if I'm pregnant or breastfeeding? ▾
This needs a careful conversation with your doctor. During pregnancy, lisdexamfetamine may increase the risk of premature delivery and low birth weight. Newborns exposed to amphetamines can show withdrawal symptoms after birth. Breastfeeding is not recommended while taking this medication because the drug passes into breast milk and may affect your baby's heart, blood pressure, and growth. If you're pregnant, planning to become pregnant, or breastfeeding, let your prescriber know before starting or continuing this medication.
Is Lisdexamfetamine available over the counter? ▾
Lisdexamfetamine is dispensed by prescription according to its FDA labeling, so it isn't sold over the counter. Your prescriber and pharmacist will determine if it's appropriate for you.
Is Lisdexamfetamine a controlled substance? ▾
Yes — Lisdexamfetamine is a federally controlled substance (Schedule II) in the United States, so how it is prescribed, refilled and dispensed is regulated by the DEA.
When was Lisdexamfetamine first available? ▾
Lisdexamfetamine has been available in the United States since at least 2007, based on FDA approval history (Drugs@FDA) and product marketing records.
Who makes Lisdexamfetamine? ▾
Lisdexamfetamine is supplied by 33 manufacturers listed in the FDA NDC Directory, including Takeda Pharmaceuticals America, Inc., Teva Pharmaceuticals, Inc., Mylan Pharmaceuticals Inc..

💬 Answers drafted from Lisdexamfetamine’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →

🧰 Keep exploring

📊Lisdexamfetamine supplement interactions126 checked — ranked by severity 🌿Drug & Supplement CheckerLisdexamfetamine vs. vitamins & herbs 💬Ask a PharmacistFree answer, usually < 24h 🔎NDC & pricing lookupFind Lisdexamfetamine NDCs & costs 🅰️Browse Drugs A–ZLook up any medication

💊 How Lisdexamfetamine comes

Lisdexamfetamine is available in 3 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Capsule

By mouth
Brands Lisdexamfetamine Dimesylate Vyvanse
How this form is used
What it may be used for
  • Treats ADHD in adults and children age 6 and older
  • Treats moderate to severe binge eating disorder in adults
  • Not recommended for weight loss or in children under age 6
Important instructions
  • Take by mouth once in the morning, with or without food; avoid afternoon doses to prevent insomnia
  • Vyvanse capsules and Lisdexamfetamine Dimesylate capsules can be swallowed whole
  • Vyvanse capsules and Lisdexamfetamine Dimesylate capsules can also be opened and the contents mixed completely into water, yogurt, or orange juice — consume the entire mixture right away and do not store it
  • Do not use unapproved methods of administration such as snorting or injecting
Available strengths 7 strengths
10 mg 20 mg 30 mg 40 mg 50 mg 60 mg
Show 1 more strength Show fewer strengths
70 mg
281 FDA-listed product records ⓘ

Chewable tablet

By mouth
Brands Lisdexamfetamine Dimesylate Vyvanse
How this form is used
What it may be used for
  • Treats ADHD in adults and children age 6 and older
  • Treats moderate to severe binge eating disorder in adults
  • Not recommended for weight loss or in children under age 6
Important instructions
  • Vyvanse chewable tablets and Lisdexamfetamine Dimesylate chewable tablets must be chewed thoroughly before swallowing
  • Take by mouth once in the morning, with or without food; avoid afternoon doses to prevent insomnia
  • Do not split a single dose; do not take less than one tablet per day
  • Vyvanse chewable tablets can be substituted for Vyvanse capsules on a milligram-for-milligram basis as directed by your prescriber
Available strengths 6 strengths
10 mg 20 mg 30 mg 40 mg 50 mg 60 mg
78 FDA-listed product records ⓘ

Oral solution

By mouth
Brands Arynta
How this form is used
What it may be used for
  • Arynta treats ADHD in adults and children age 6 and older
  • Arynta treats moderate to severe binge eating disorder in adults
  • Arynta is not recommended for weight loss or in children under age 6
Important instructions
  • Arynta is taken by mouth once in the morning, with or without food; avoid afternoon doses to prevent insomnia
  • Arynta comes with an oral dosing syringe and bottle adapter — use only these provided tools to measure and give the dose
  • Insert the bottle adapter firmly before first use and keep it in place for the entire time the bottle is in use
  • Discard any remaining Arynta 30 days after first opening the bottle
Available strengths 1 strength
10 mg/mL
5 FDA-listed product records ⓘ

📊 Lisdexamfetamine across the U.S. market

How Lisdexamfetamine appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

3
Dose forms ⓘ
33
Manufacturers
3
Brand names
376
FDA-listed product records ⓘ
2007
First marketed ⓘ

FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

Also listed with the FDA, not a patient dose form: Powder (12) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.

Takeda Pharmaceuticals America, Inc.10%
Teva Pharmaceuticals, Inc.9%
Mylan Pharmaceuticals Inc.7%
Sun Pharmaceutical Industries, Inc.7%
Amneal Pharmaceuticals LLC7%
Alvogen Inc.6%
Other makers54%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

📈 How widely Lisdexamfetamine is used

A general measure of how commonly Lisdexamfetamine is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.

Think of this as a proxy for how widely Lisdexamfetamine is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.

3,941,773
Medicaid prescriptions filled (Q1–Q4 2025)
$1.23B gross Medicaid reimbursement (before mandatory rebates — net cost is lower)

How commonly is Lisdexamfetamine prescribed? Of the 1,596 medications we measure, Lisdexamfetamine ranks #53 by Medicaid prescriptions — more than 97% of them.

Where Lisdexamfetamine ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5
Total prescriptions — #53 of 1,596
#48 Cyclobenzaprine 4,437,147 Rx #49 Triamcinolone Topical 4,329,207 Rx #50 Duloxetine 4,105,865 Rx #51 Methadone 4,056,849 Rx #52 Guanfacine 4,043,576 Rx #53 Lisdexamfetamine 3,941,773 Rx #54 Cephalexin 3,933,834 Rx #55 Rosuvastatin 3,856,155 Rx #56 Insulin Glargine (rDNA... 3,731,821 Rx #57 Clonazepam 3,602,972 Rx #58 Fluconazole 3,462,620 Rx

Utilization by Lisdexamfetamine product

Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.

The 30 mg oral capsule is the most-dispensed Lisdexamfetamine product — about 22% of these Medicaid prescriptions.

lisdexamfetamine dimesylate 30 MG Oral Capsule Most dispensed

853,335 Medicaid prescriptions (Q1–Q4 2025) 22% of Lisdexamfetamine prescriptions shown $266.9M gross reimbursement (before rebates) ≈ $313 per prescription (gross)

Summed across the 16 of 23 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 854834

lisdexamfetamine dimesylate 40 MG Oral Capsule

765,604 Medicaid prescriptions (Q1–Q4 2025) 19% of Lisdexamfetamine prescriptions shown $237M gross reimbursement (before rebates) ≈ $310 per prescription (gross)

Summed across the 16 of 21 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 854838

lisdexamfetamine dimesylate 50 MG Oral Capsule

596,763 Medicaid prescriptions (Q1–Q4 2025) 15% of Lisdexamfetamine prescriptions shown $185.2M gross reimbursement (before rebates) ≈ $310 per prescription (gross)

Summed across the 16 of 22 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 854850

lisdexamfetamine dimesylate 20 MG Oral Capsule

565,159 Medicaid prescriptions (Q1–Q4 2025) 14% of Lisdexamfetamine prescriptions shown $176.8M gross reimbursement (before rebates) ≈ $313 per prescription (gross)

Summed across the 16 of 22 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 854830

lisdexamfetamine dimesylate 60 MG Oral Capsule

380,869 Medicaid prescriptions (Q1–Q4 2025) 10% of Lisdexamfetamine prescriptions shown $117.8M gross reimbursement (before rebates) ≈ $309 per prescription (gross)

Summed across the 15 of 21 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 854846

lisdexamfetamine dimesylate 70 MG Oral Capsule

359,619 Medicaid prescriptions (Q1–Q4 2025) 9% of Lisdexamfetamine prescriptions shown $111.5M gross reimbursement (before rebates) ≈ $310 per prescription (gross)

Summed across the 14 of 24 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 854842

lisdexamfetamine dimesylate 10 MG Oral Capsule

228,563 Medicaid prescriptions (Q1–Q4 2025) 6% of Lisdexamfetamine prescriptions shown $73.8M gross reimbursement (before rebates) ≈ $323 per prescription (gross)

Summed across the 15 of 17 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1593856

lisdexamfetamine dimesylate 20 MG Chewable Tablet

61,782 Medicaid prescriptions (Q1–Q4 2025) 2% of Lisdexamfetamine prescriptions shown $18.4M gross reimbursement (before rebates) ≈ $298 per prescription (gross)

Summed across the 7 of 7 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1871462

lisdexamfetamine dimesylate 10 MG Chewable Tablet

44,808 Medicaid prescriptions (Q1–Q4 2025) 1% of Lisdexamfetamine prescriptions shown $13.8M gross reimbursement (before rebates) ≈ $307 per prescription (gross)

Summed across the 7 of 7 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1871464

lisdexamfetamine dimesylate 30 MG Chewable Tablet

44,241 Medicaid prescriptions (Q1–Q4 2025) 1% of Lisdexamfetamine prescriptions shown $13.1M gross reimbursement (before rebates) ≈ $297 per prescription (gross)

Summed across the 7 of 7 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1871460

lisdexamfetamine dimesylate 40 MG Chewable Tablet

23,184 Medicaid prescriptions (Q1–Q4 2025) <1% of Lisdexamfetamine prescriptions shown $7M gross reimbursement (before rebates) ≈ $302 per prescription (gross)

Summed across the 7 of 7 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1871456

lisdexamfetamine dimesylate 50 MG Chewable Tablet

10,736 Medicaid prescriptions (Q1–Q4 2025) <1% of Lisdexamfetamine prescriptions shown $3.2M gross reimbursement (before rebates) ≈ $294 per prescription (gross)

Summed across the 6 of 7 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1871468

lisdexamfetamine dimesylate 60 MG Chewable Tablet

7,110 Medicaid prescriptions (Q1–Q4 2025) <1% of Lisdexamfetamine prescriptions shown $2.1M gross reimbursement (before rebates) ≈ $300 per prescription (gross)

Summed across the 6 of 7 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1871466

Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.

Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Lisdexamfetamine, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 148 of 192 listed Lisdexamfetamine NDCs with Medicaid activity.

🔍 Compare Lisdexamfetamine products

A representative set of FDA-listed product records for Lisdexamfetamine — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Showing 200 of 376 products — FDA National Drug Code Directory. See every product, package size and price: browse all 376 Lisdexamfetamine NDCs →

RxNorm Concept Web — From Ingredient to Every Form and Strength

This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.

Ingredient (IN) Lisdexamfetamine RxCUI 700810 3 dose forms · 14 strengths
  3. Dose form (SCDF) Oral Solution RxCUI 2726045 In current FDA listings
    Clinical drug / strength (SCD) dimesylate 10 MG/ML RxCUI 2726048

Look up RxCUI 700810 in the RxCUI Atlas →

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

🏷️ Sold under these brand names

Vyvanse Arynta Lisdexamfetamine Dimesylate

🏭 Manufacturers & labelers

Takeda Pharmaceuticals America, Inc. 39 Teva Pharmaceuticals, Inc. 33 Mylan Pharmaceuticals Inc. 28 Sun Pharmaceutical Industries, Inc. 26 Amneal Pharmaceuticals LLC 25 Alvogen Inc. 21 SpecGx LLC 21 Granules Pharmaceuticals Inc. 19 Apotex Corp. 14 Solco Healthcare US,LLC 14 Sandoz Inc 14 Elite Laboratories, Inc. 14 Lannett Company, Inc. 14 Camber Pharmaceuticals, Inc. 13 Hikma Pharmaceuticals USA Inc. 13 Bryant Ranch Prepack 9 Ascent Pharmaceuticals, Inc. 7 Rhodes Pharmaceuticals LLC 7 American Health Packaging 6 Novadoz Pharmaceuticals LLC 6 AvKARE 6 Ascent Pharmaceuticals, Inc 6 Azurity Pharmaceuticals, Inc. 5 Cambrex Charles City, Inc 4

…and 9 more on the FDA NDC directory.

RxNorm drug class

Lisdexamfetamine belongs to the Central Nervous System Stimulant class.

Pharmacologic class Central Nervous System Stimulant
Drug family (ATC) Centrally acting sympathomimetics

Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.

🔬 Where this comes from

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. ✓ Linked label effective May 22, 2026
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Lisdexamfetamine.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.
🧾 Clinical label set — FDA-filed SPL labels retained for Lisdexamfetamine after exact ingredient or ingredient-combination matching and applicable route/form matching
Clinical labels in scope
32
NDC products indexed
376
Distinct labelers/manufacturers represented
33
Linked representative label ⓘ
Mylan Pharmaceuticals Inc.
Linked label effective
May 22, 2026
Composite sections available
25
Linked SPL Set ID
efbde0f6-b848-4664-b741-c6c630e66108
Linked SPL Document ID
6e77cd71-95ae-4fa8-830b-ab62b714e4b9
Open the linked representative label on DailyMed ↗

How we combine label and product data

HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 32 FDA-filed SPL label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.

For canonical ingredient pages, bounded product-attributed indication and administration excerpts may be added to the AI evidence, and the generator is instructed to preserve available product, brand, route, and form qualifiers instead of treating one label as universal. Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. Mylan Pharmaceuticals Inc. is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.

This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.